Curanex regains Nasdaq minimum bid price compliance after 1-for-20 reverse split

Curanex Pharmaceuticals Inc

On Sept 3, 2026, Nasdaq confirmed closing bid price >= $1.00 for 10 straight business days (Aug 20-Sep 2).
Company effected 1-for-20 reverse stock split on Aug 20, 2026 to cure bid price deficiency.
Originally notified Nov 5, 2025 of non-compliance with Nasdaq Listing Rule 5550(a)(2).
Nasdaq has closed the matter; CURX remains listed on The Nasdaq Capital Market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.